MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates

Company Performance - MacroGenics reported a quarterly loss of $0.65 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.61, and an improvement from a loss of $0.84 per share a year ago, indicating a surprise of -6.56% [1] - The company posted revenues of $13.19 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 5.45%, but showing an increase from $9.1 million in the same quarter last year [2] - Over the last four quarters, MacroGenics has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2] Stock Performance - MacroGenics shares have declined approximately 51.1% since the beginning of the year, contrasting with the S&P 500's decline of -0.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.50 on revenues of $18.13 million, and for the current fiscal year, it is -$2.21 on revenues of $78.51 million [7] Industry Outlook - The Medical - Products industry, to which MacroGenics belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - The earnings outlook for MacroGenics is favorable, with a Zacks Rank of 2 (Buy), suggesting that the shares are expected to outperform the market in the near future [6]